Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.73 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26837670 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20208270 | 0.89 | CRBN (0.71) | CRBNDDB1STAT3HDAC8GRAMD1A | |
| SCHEMBL18476414 | 0.89 | CRBN (0.71) | CRBNDDB1STAT3HDAC8GRAMD1A | |
| SCHEMBL25473202 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20208349 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL24046261 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20208237 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL17859116 | 0.89 | CRBN (0.71) | CRBNDDB1STAT3HDAC8GRAMD1A | |
| SCHEMBL20791980 | 0.89 | CRBN (0.71) | CRBNDDB1STAT3HDAC8GRAMD1A | |
| SCHEMBL20208239 | 0.89 | CRBN (0.88) | CRBNDDB1STAT3GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544957-B1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11578075-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578075-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10899768-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3544957-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018098280-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098280-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885WDR5 963/4885 |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885WDR5 963/4885 |
| US-10899768-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885WDR5 963/4885 |
| US-11578075-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885WDR5 963/4885 |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885WDR5 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.